探索神经元特异性类固醇合成和阿尔茨海默氏病中DHEAS治疗
Hong-Yi Lin1, Yin-Hsun Feng2, Tzu-Jen Kao3
1Taipei Neuroscience Institute, Taipei Medical University, Taipei 110, Taiwan.
概括
阿尔茨海默病与神经元中的类固醇合成受损有关. 恢复类固醇水平,就像DHEAS治疗一样,可以改善认知功能并减少疾病病理.
科学领域:
- 神经生物学 神经生物学 神经生物学
- 生物化学 生物化学
- 内分泌学 在内分泌学.
背景情况:
- 阿尔茨海默病 (AD) 涉及认知能力下降和记忆力丧失.
- 新出现的证据表明,类固醇合成在AD病理学中起着作用.
- 类固醇酶及其产物对神经元功能至关重要.
研究的目的:
- 研究AD中神经元中的类固醇合成.
- 在AD模型和人体样本中分析类固醇生成酶和类固醇表达的变化.
- 评估脱水埃二硫酸盐 (DHEAS) 在阿尔茨海默病中的治疗潜力.
主要方法:
- 免疫光检测神经元中的蛋白质同局部化.
- 在AD小鼠模型和人类大脑组织中对类固醇酶表达的分析.
- 患者血清的类固醇代谢分析.
- 评估DHEAS治疗对AD小鼠认知和病理学的影响.
主要成果:
- 类固醇酶 (CYP17A1,StAR) 在前突触神经元中与α-synuclein共局部,表明活性,神经元特异性的类固醇合成.
- 在AD小鼠模型和人类AD/MS组织中,关键类固醇酶 (Cyp11a1,Cyp17a1,Star) 的表达减少.
- 血清类固醇组分析显示,在阿尔茨海默病患者中,降低调节的类固醇.
- 在AD小鼠中,DHEAS治疗改善了认知功能,并减少了粉样β (Aβ) 积累.
结论:
- 一个神经元特定的类固醇合成途径在AD病理学中起作用.
- 缺陷的类固醇合成是神经退行性疾病的特征,如AD.
- 向类固醇合成途径,特别是DHEAS,显示了对AD的治疗前景.
更多相关视频
04:22Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease
Published on: May 20, 2024
815
06:44Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)
Published on: January 10, 2025
455
相关概念视频
01:22Alzheimer's Disease: Treatment
172
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
172
01:26Alzheimer's Disease: Overview
456
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
456
01:29Drugs Affecting Neurotransmitter Synthesis
1.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
114
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
114
01:21Drugs Affecting Neurotransmitter Release or Uptake
1.0K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.0K
01:20Myasthenia Gravis: Overview and Treatment
1.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.3K